Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This study found that spironolactone reduced fish fecundity and caused masculinization of females at certain concentrations, while having no effect on Daphnia magna reproduction, underscoring concerns for environmental exposure to vertebrates.

St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.

This study suggests that nanostructured lipid carriers loaded with spironolactone might improve localized delivery to hair follicles for treating androgenic alopecia, potentially minimizing systemic side effects.

This study found that compound 4 from Urtica triangularis subsp. pinnatifida exhibited stronger anti-BPH activity against BPH-1 cells with an IC50 of 79.75 μM compared to finasteride's IC50 of 91.8 μM, while compounds 1, 2, and 5 showed moderate activity.

This article presents a case of trichostasis spinulosa, a common but often unrecognized disorder, diagnosed through dermoscopic examination of black macules revealing bundled vellus hairs, with the patient declining treatment.

In this study, estetrol (E4) treatment was associated with increased hair growth in ex vivo human hair follicles, suggesting its potential as a treatment for hair loss disorders.

In this study, the researchers used molecular docking to identify Erythrabyssin II from Erythrina subumbrans as a potential candidate for anti-alopecia treatment, comparable to minoxidil, suggesting clinical trials are needed to evaluate its pharmacological effects.

Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study analyzed the affinity, stability, and pharmacokinetics of compounds from Sansevieria trifasciata, reporting that three compounds showed promising molecular docking results against the androgen receptor and satisfactory pharmacokinetic profiles, similar to minoxidil, in an in-silico setting.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

In this study, a herbal preparation inhibited the conversion of testosterone to DHT and its binding on hair roots in vitro, suggesting potential as an alternative treatment for androgenic alopecia without the safety concerns associated with finasteride.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

In this study, finasteride inhibited progesterone synthesis in mouse-derived MA-10 Leydig tumor cells by blocking cholesterol side-chain cleavage, but human and rat cells showed minimal sensitivity.

This study predicted that 6-hydroxy genistein, coreximine, and scoulerine from Dadap leaves may act as anti-alopecia agents by interacting with JAK2, but further in-vivo testing is needed.

This narrative review discusses spironolactone as a treatment for female pattern hair loss and reports no new results, aiming to provoke discussion on treatments and research in androgenetic alopecia.

This review systematically examined recent advancements in spironolactone-loaded nanocarriers, revealing that lipid and vesicular nanoparticles enhance bioavailability and skin penetration for treating androgen-dependent disorders, but highlighted the need for further clinical studies to optimize their use.

This study found that Ocimum basilicum L. showed the highest 5α-reductase inhibitory activity among ten Thai plants, despite no correlation between enzyme inhibition and total phenolic content.

This study found that Sinseon-yukza-hwan extract has strong antioxidative properties, effectively inhibiting free radical generation, which supports its potential use as a natural antioxidant.

This study reported that Juniperus sabina needle extract showed significant anti-butyrylcholinesterase activity, suggesting potential medicinal value due to high podophyllotoxin levels.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

The researchers reported that sterol surfactants with a bulky planar structure effectively solubilized ultraviolet ray absorbers, offering a stable solution more efficiently than other surfactants.

This study suggests that the Anetholea anisita extract improved scalp health by increasing specialized pro-resolving mediators and reducing pro-inflammatory markers, leading to decreased dandruff and enhanced hair brightness in dandruff sufferers.

In this study, among postmenopausal women with female androgenetic alopecia, the combination of Pygeum africanum and Serenoa repens extracts at higher doses plus MSM significantly increased total hair growth and hair resistance compared to a lower dose formulation after 16 weeks.

This study showed that Thujae occidentalis semen extract inhibited 5alpha-reductase type 2 in laboratory tests and reduced androgen-related hair loss in animal models, suggesting potential use for male pattern baldness.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.